Pipeline

BEAM Alliance

The pipeline of antimicrobial products under development is thin. But innovative.

Indeed, the antimicrobial products under development display a variety of pharmacological effects and applications.

They are described in the BEAM Infection Curve (BIC); read the memo to find out more.

Take a look at all these products that could save lives in the future.

BEAM Alliance

Pipeline RX

Click on column headers to sort the table

memberproductbic*typetargets/indicationsdevelopment
stage
Syntinel BiologicsminiSimCells1aVaccinevariousPre-clinical
Syntinel BiologicsminiSimCells3aOtherE. coli / Urinary tract infections (UTIs)Pre-clinical
Syntinel BiologicsSimCells1aVaccineE. coli / Urinary tract infections (UTIs)Pre-clinical
Syntinel BiologicsSimCells1aVaccineS. aureus, P. aeruginosa. / Lower respiratory tract infections (LRTIs): hospital and ventilator acquired pneumonia (HAP/VAP)Pre-clinical
smartbaxGram (+)3aNMEGram positive / ABSSI, BSIDiscovery
smartbaxGram (-)3aNMEGram negativeDiscovery
smartbaxGram (-)3aNMEGram negative / cUTILead opt
Polaroid TherapeuticsPOLTX_Fiber5aOtherAcute and chronic woundsMarketed
ObulytixPrecision Lysin Therapeutics (PLTs)3aProtein/PeptideMultidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii / Polymicrobial bacterial wound infectionsDiscovery
ObulytixPrecision Lysin Therapeutics (PLTs)3aProtein/PeptideMultidrug-resistant Acinetobacter baumannii / Hospital-acquired bloodstream infections in critically ill patientsLead opt
NexaBiome Life Sciences LtdStaphix-DFI3aPhageStaphylococcus aureus / Diabetic Foot InfectionsPre-clinical
INTELIPHAGEGMP Phage API for Therapeutic usePhageDifficult-to-treat bacterial infections: bone & joint, respiratory tract, urinary tract, skin & soft tissues, bloodstream infectionsPre-clinical
Infex TherapeuticsBamA inhibitors3aNMEEnterobacterales (E. coli and K. pneumoniae), P. aeruginosa /MDR gram-negative pathogensLead opt
Disperazol PharmaP3-RTI-0191bNMEP.aeruginosa and E.coli / UTI and cUTILead opt
Disperazol PharmaP3-RTI-0193dNMEP.aeruginosa and E.coli / UTI and cUTILead opt
Disperazol PharmaP2-RTI-0061bNMEP.aeruginosa and E.coli / UTI and cUTILead opt
Disperazol PharmaP2-RTI-0063dNMEP.aeruginosa and E.coli / UTI and cUTILead opt
Debiopharm InternationalDebio 14554bOtherInflammatory bowel diseasePre-clinical
Brigid BiomAbs3cAntibodyCandida & Aspergillus spp / Drug-resistant fungal infectionsPre-clinical
Basilea Pharmaceutica InternationalBAL2062 3aNMEInvasive aspergillosis Phase I
Basilea Pharmaceutica InternationalBAL2420 (LptA inhibitor)3aNMESevere Enterobacteriaceae infections Phase I
AdjuTec PharmaAPC2773dNMEResistant fungal infectionsDiscovery
AdjuTec PharmaAPC247 (explorative)3dNMETreatment of resistant fungiLead opt
AdjuTec PharmaAPC247 (undecided antibiotic)3dNMETreatment of resistant G-bacteriaPre-clinical
Basilea Pharmaceutica InternationalCeftibuten-ledaborbactam3aNMEComplicated urinary tract infections (cUTI)Phase II
AdjuTec PharmaAPC302 (incl cefepime)3dNMETreatment of resistant G-bacteriaPre-clinical
AB2 TherapeuticsAnti-A. fumigatus3aNMEAspergillus fumigatus / Tract respiratory infectionsDiscovery
AB2 TherapeuticsAnti-Gramnegative3aNMEKlebsiella pneumoniae, Escherichia coli, A. baumannii / Bloodstream and lower respiratory tract infectionsDiscovery
AB2 TherapeuticsAnti-S. aureus-023aNMEStaphylococcus aureus / Severe life-threatening infectionsDiscovery
AB2 TherapeuticsAnti-S. aureus-013aNMEStaphylococcus aureus / Severe life-threatening infectionsLead opt
AB2 TherapeuticsAnti-A. baumannii-013aNMEAcinetobacter baumannii / Severe life-threatiening infectionsPre-clinical
AdjuTec PharmaAPC1483dNMEAntibiotic-resistant infections caused by MBL-producing pathogensPhase I
SNIPR BiomeSNIPR-lung3aOtherPseudomonas aerguinosa / Chronic infections in people with CF/bronchiectasisLead opt
SNIPR BiomeSNIPR-resensitize5bOtherTop 9 AMR pathogens / AMR purgingLead opt
SNIPR BiomeSNIPR-EED5bOtherE. coli, K. pneumoniae - Environmental enteric dysfunctionPre-clinical
SNIPR BiomeSNIPR001-IV3aOtherMDR E. coli / uUTI/Sepsis, Kidney transplant / Expanded AccessPre-clinical
SNIPR BiomeSNIPR001-Oral1bOtherE. coli / Blood infections in Hema. cancersPhase II
AUROBAC THERAPEUTICSATX1014aNMETreatment of early septic shock to prevent progression and improve outcomePhase II
AUROBAC THERAPEUTICSATX53aNMEGram-negatives pathogens infectionsDiscovery
AMR-Bio LtdXF-73 Drugs Research1bNMETreatment & prevention of topical fungal infectionsPre-clinical
AMR-Bio LtdXF-73 Dermal3aNMETreatment & prevention of burn wound infectionsPre-clinical
AMR-Bio LtdXF-73 Nasal3aNMEPrevention of post surgical Staphylococcal (including MRSA) infectionsPhase II
Telum TherapeuticsEpleTTX33aProtein/PeptideEnterococcus faecium (VRE) / Bloodstream infection / bacteremia and sepsisDiscovery
Telum TherapeuticsEpleTTX23aProtein/PeptideStaphylococcus aureus (MRSA) / Prosthetic joint infection (PJI)Lead opt
Telum TherapeuticsEpleTTX13aProtein/PeptideAcinetobacter baumannii (CRA) / HABP/VABP (Gram-negative)IND/CTA ready
Basilea Pharmaceutica InternationalFosmanogepix3aNMEInvasive mold infections (including invasive aspergillosis, fusariosis, Scedoporium and Lomentospora, mucormycosis and other rare mold infections)Phase III
Basilea Pharmaceutica InternationalFosmanogepix3aNMECandidemia / invasive candidiasis (including Candida auris)Phase III
Basilea Pharmaceutica InternationalCresemba® isavuconazole 3aNMEAspergillosis (including invasive aspergillosis and chronic pulmonary aspergillosis), mucormycosis and cryptococcosis [Japan]Marketed
Basilea Pharmaceutica InternationalCresemba® isavuconazole 3aNMEInvasive aspergillosis and mucormycosis [US, EU and several other countries]Marketed
OM PharmaUro-Vaxom®1aOtherRecurrent lower urinary tract infections (i.e. cystitis)Marketed
OM PharmaBroncho-Vaxom® (Bacterial Lysates – OM-85)1aOtherRecurrent Respiratory Tract Infections (RTIs)Marketed
OM PharmaOM-851aOtherRespiratory Tract Infections (RTIs)Phase II
OM PharmaOM-891aOtherCommunity acquired pneumonia (CAP) and other upper respiratory infections (URTI) (sinusitis/otitis media etc)Phase I
OM PharmaOM-851aOtherUncomplicated urinary tract infections (uUTI)Phase I
DevsHealthMulti-resistant s. aureus novel treatmentNMES. aureus (methicillin resistant) / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Discovery
ArrePathAP-0013aNMEE. coli, K. pneumoniae, Enterobacter spp., Citrobacter spp., Other Enterobacterales, Salmonella spp., Shigella spp., E. faecium, N. gonorrhoeae, H. influenzae / Complicated urinary tract infections (cUTI)Lead opt
anti-virulence agents3aNMEMycobacterium tuberculosis / Cystic fibrosis associated infectionsIND/CTA ready
Santero TherapeuticsSAN-Sa13aNMES. aureusPre-clinical
UltupharmaULT13aNMEE. faecium, S. aureus, S. pneumoniae, Group A Streptococci / Complicated urinary tract infections (cUTI)IND/CTA ready
UltupharmaULT2C3aNMEE. coli, K. pneumoniae, Enterobacter spp., Salmonella spp., S. aureus, S. pneumoniae, H. influenzae, Group A Streptococci /Skin and Skin-structure infections (ABSSSI)IND/CTA ready
UltupharmaULT2B3aNMEE. coli, K. pneumoniae, Enterobacter spp., Salmonella spp., Shigella spp., H. influenzae / Cystic fibrosis associated infectionsIND/CTA ready
UltupharmaULT2A3aNMEE. coli, K. pneumoniae, Enterobacter spp., Salmonella spp., Shigella spp., S. aureus, H. influenzae / Cystic fibrosis associated infectionsIND/CTA ready
UltupharmaULT33aProtein/PeptideA. baumannii, E. coli, K. pneumoniae, Enterobacter spp., Other Enterobacterales, P. aeruginosa / Skin and Skin-structure infections (ABSSSI)IND/CTA ready
VAXDYNAcinetoVax1aVaccineA. baumannii / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Pre-clinical
VAXDYNEcoVax1aVaccineA. baumannii, E. coli / Bloodstream infectionsPre-clinical
VAXDYNP-Vax1aVaccineA. baumannii / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Pre-clinical
VAXDYNK-Vax1aVaccineA. baumannii, K. pneumoniae / Bloodstream infectionsIND/CTA ready
Arivin therapeuticsT2625 Topical3aNMEK. pneumoniae, P. aeruginosa / Chronic open woundsLead opt
Arivin therapeuticsViri-01 inhaled (DPI)3aNMERecurring respiratory infections NCFB / CFPre-clinical
Thioredoxin SystemsEbsArgent3aNMEE. coli, A. baumannii, P. aeruginosa, S. aureus / Complicated urinary tract infections (cUTI)Pre-clinical
Nexbiome TherapeuticsAntibiome3aNMEMultiples resistants Gram+ and Gram-Discovery
Infex TherapeuticsGON-X3aNMEN. Gonorrhoeae / Resistant Neisseria GonorrhoeaLead opt
Infex TherapeuticsVAP-X4aNMEP. aeruginosa / Hospital-acquired or Ventilator-acquired bacterial Pneumoniae (HABP/VABP)Lead opt
Disperazol PharmaP1-335-H63dNMEP. aeruginosa / Complicated urinary tract infections (cUTI)Pre-clinical
Disperazol PharmaP1-335-H61bNMEP. aeruginosa / Complicated urinary tract infections (cUTI)Pre-clinical
Osta 27OtherA. baumannii, P. aeruginosa, M. tuberculosis / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Pre-clinical
NanoRevivStaph-EX3aOtherS. aureus, Group A Streptococci, Group B Streptococci / Skeletal InfectionsPre-clinical
discoveric bio betaDB-1003aNMEEnterobacterales / cUTI, HABP, and associated BSIDiscovery
discoveric bio betaDB-2003aNMEP. aeruginosa / HABP, and associated BSIDiscovery
Omnix MedicalOMN713aProtein/PeptideAnimal-Health relevant pathogens / Veterinary indicationPre-clinical
Omnix MedicalOMN513aProtein/PeptideEnterobacter spp., P. aeruginosa, S. aureus / Cystic Fibrosis, non-CF- Bronchiestasis and pulmunary infectionsPre-clinical
Infex TherapeuticsRDX-023aNMEGram-negative AMR infectionsLead opt
Infex TherapeuticsMET-X3dNMEA. baumannii, P. aeruginosa / Hospital-acquired or Ventilator-acquired bacterial Pneumoniae (HABP/VABP)IND/CTA ready
Infex TherapeuticsRESP-X3cAntibodyP. aeruginosa / Non-cystic-fibrosis bronchiectasisPhase II
F2GOlorofim3aNMEDHODH inhibitor/Aspergillosis refractory, resistant or intolerant to azoles; Lomentospora prolificans, Scedosporium, Fusarium and Scopulariopsis species; Coccidioidomycosis refractory / Invasive aspergillosis, Coccidioidomycosis, Scedosporium, Lomentospora and Other rare and endemic mold infectionsPhase III
AdjuTec PharmaAPC301 (incl meropenem)3dNMETreatment of resistant G-bacteria / Complicated infections with multidrug-resistant Gram negative bacteriaPhase I
Selmodslm 5003aNMEE. coli; Broad-spectrum G+/G- / Complicated urinary tract infections (cUTI)IND/CTA ready
Selmodslm 3003aNMEK. pneumoniae; Broad-spectrum G+/G- / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Lead opt
Selmodslm 1003aNMECandida albicans, Aspergillus fumigatus, Candida auris / Invasive spergillosis, Oral Candidiasis, Bronchopulmonary aspergillosisaLead opt
BioVersysBV100 – novel MoA3aNMESerious Hospital infections / A. baumanniiPhase III
BioVersysalpibectir – novel potentiator MoA3dNMEMDR-TB, TB Meningitis (TBM)Phase II
ANTABIOMEM-PIL (formerly MEM-ANT3310)3dNMECarbapenem-resistant A. baumannii, Carbapenem-resistant enterobacterales, P. aeruginosa / HAP/VAPPhase II
Omnix MedicalOMN63aProtein/PeptideA. baumannii, P. aeruginosa, E. coli, K. pneumoniae; Enterobacter spp / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Phase II
tamrisaTMR0203aNMEEnterobacterales, P. aeruginosa, A. baumannii / Complicated urinary tract infections (cUTI)Lead opt
tamrisaTMR0103aNMEEnterobacterales / Complicated urinary tract infections (cUTI)Pre-clinical
IMMUNETHEPmAb Program (mAb_Ent; mAb_Staph; mAb_Strep)3cAntibodyE-coli, K. pneumoniae, S. aureus, S. pneumoniae, Group A Streptococci, Group B Streptococci / Hospital-acquired or Ventilator-acquired bacterial pneumoniae (HABP/VABP)Lead opt
IMMUNETHEPPNV Program (PNV_Ent; PNV_Staph; PNV_Strep)1aVaccineE-coli, K. pneumoniae, S. aureus, S. pneumoniae, Group A Streptococci, Group B Streptococci / Healthcare associated CAPIND/CTA ready
HypharmHY-1331bProtein/PeptideS. aureus including Methicillin resistant S. aureus / Decolonization of S. aureus including MRSA to prevent postoperative infectionsPhase I
Debiopharm InternationalDebio14533aNMENeisseria gonorrhoeae / GonorrhoeaPhase I
Debiopharm InternationalAfabicin (Debio 1450)3aNMEStaphylococcus spp./ Bone and joint infections, ABSSSIPhase II
Centauri TherapeuticsABX013cOtherA. baumannii; P. aeruginosa; Escherichia coli; Klebsiella pneumoniae; Enterobacter spp./Healthcare-asscoiated infectionsPhase I
Centauri TherapeuticsABX023cOtherP. aeruginosa/Healthcare-asscoiated infectionsPre-clinical
BioVersysBV200 – novel anti-virulence MoA4aNMES. aureusPre-clinical
BioVersysBV500 – novel series3aNMENTM infectionsLead opt
Basilea Pharmaceutica InternationalZevtera® ceftobiprole 3aNMEHospital- and community-acquired bacterial pneumonia (HABP, CABP) - [major European and several other countries]Marketed
Basilea Pharmaceutica InternationalZevtera® ceftobiprole 3aNMES. aureus bacteremia (SAB), acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) - [United States]Marketed
ANTABIOPEi3cNMEP. aeruginosa / Non-CF bronchiectasis associated infectionsPre-clinical
AktheliaAKT-0113cNMEE. coli, Salmonella spp / Febrile NeutropeniaPre-clinical
< PreviousPage 1/11show allNext >

*BIC: BEAM Infection Curve

The displayed information are not necessarily reflecting the official current position of each BEAM members; please refer to each company’s website for updated information, or contact them directly.

Pipeline DX

Click on column headers to sort the table

memberkit/testtargeted resultpathogens/indicationslab workflowdevelopment stage
ProfionicsProfionicsHost-response genomic and metabolite biomarker testing to screen and detect sepsisDiagnosis of sepsis across patient cohorts: neonatal, paediatric, maternal and adultFrom whole blood
 
<2h		Development Phase
NosticsDUTIID/AST combinedMultiplex bacteria (label-free) /
Urinary Tract infections		From urine
Surface Enhanced Raman Spectroscopy, <10min
<30 minutes		Feasibility Phase
BugSeeBugInnoculatorID/AST combinedGram+, Gram-, Fungi /
Bloodstream infections		From whole blood
Microarray chip/reader
<2h		Development Phase
BugSeeBugNucleoAMR Mechanism of Resistance IDGram+, Gram-, Fungi /
Bloodstream infections		From whole blood
PCR/qPCR
<30 minutes		System Integration and Testing
BugSeeBugPhenoID/AST combinedGram+, Gram-, Fungi /
Bloodstream infections		From positive blood culture
MALDI-TOF
<30 minutes		System Integration and Testing
MicrobiraMAAP-IRPathogen ID82% of Routine Clinical Isolates /
Gram type 99.2% Genus 90.5% Species 88.5%		From isolated colony
Infrared spectroscopy
<30 minutes		Clinical Validation EU and/or US
MicrobiraMAP-IR KPC -nonKPCAMR Mechanism of Resistance IDKlebsiella pneumoniae /
99 % accuracy 		From isolated colony
Infrared spectroscopy
<30 minutes		Prototype in Lab
NosticsDUTIPathogen IDMultiplex bacteria (label-free) /
Urinary Tract infections		From urine
Surface Enhanced Raman Spectroscopy, <10min
<30 minutes		Development Phase
< PreviousPage 1/1Next >

The displayed information are not necessarily reflecting the official current position of each BEAM members; please refer to each company’s website for updated information, or contact them directly.

BEAM Alliance ©2026

Legal notice | Photo credits

Connect with us